FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056564143> ?p ?o ?g. }

• W2056564143 abstract "AF-6/afadin plays an important role in the formation of adherence junctions. In breast and colon cancer, loss of AF-6/afadin induces cell migration and cell invasion. We aimed to elucidate the role of AF-6/afadin in human endometrial cancer.Morphology and AF-6/afadin expression in endometrial cancer cell lines was investigated by 3-dimensional culture. We used Matrigel invasion assay to demonstrate AF-6/afadin knockdown induced invasive capability. Cell proliferation assay was performed to estimate chemoresistance to doxorubicin, paclitaxel and cisplatin induced by AF-6/afadin knockdown. The associations between AF-6/afadin expression and clinicopathological status were determined by immunohistochemical analysis in endometrial cancer tissues. Informed consent was obtained from all patients before the study.The majority of cell clumps in 3-dimensional cultures of Ishikawa cells that strongly expressed AF-6/afadin showed round gland-like structures. In contrast, the cell clumps in 3-dimensional cultures of HEC1A and AN3CA cells-both weakly expressing AF-6/afadin-showed irregular gland-like structures and disorganized colonies with no gland-like structures, respectively. AF-6/afadin knockdown resulted in reduced number of gland-like structures in 3-dimensional cultures and enhancement of cell invasion and phosphorylation of ERK1/2 and Src in the highly AF-6/afadin-expressing endometrial cancer cell line. Inhibitors of MAPK/ERK kinase (MEK) (U0126) and Src (SU6656) suppressed the AF-6/afadin knockdown-induced invasive capability. AF-6/afadin knockdown induced chemoresistance to doxorubicin, paclitaxel and cisplatin in Ishikawa cells, not in HEC1A. Immunohistochemical analysis showed that AF-6/afadin expression was significantly associated with myometrial invasion and high histological grade.AF-6/afadin regulates cell morphology and invasiveness. Invasive capability is partly regulated through the ERK and Src pathway. The inhibitors to these pathways might be molecular-targeted drugs which suppress myometrial invasion in endometrial cancer. AF-6/afadin could be a useful selection marker for fertility-sparing therapy for patients with atypical hyperplasia or grade 1 endometrioid adenocarcinoma with no myometrial invasion. AF-6/afadin knockdown induced chemoresistance especially to cisplatin. Therefore, loss of AF-6/afadin might be a predictive marker of chemoresistance to cisplatin." @default.
• W2056564143 created "2016-06-24" @default.
• W2056564143 creator A5007445460 @default.
• W2056564143 creator A5020255729 @default.
• W2056564143 creator A5022080735 @default.
• W2056564143 creator A5065739944 @default.
• W2056564143 creator A5085834699 @default.
• W2056564143 creator A5085871218 @default.
• W2056564143 creator A5086107574 @default.
• W2056564143 date "2015-04-12" @default.
• W2056564143 modified "2023-10-02" @default.
• W2056564143 title "Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer" @default.
• W2056564143 cites W1487614653 @default.
• W2056564143 cites W1808636780 @default.
• W2056564143 cites W1969076427 @default.
• W2056564143 cites W1972431425 @default.
• W2056564143 cites W1978583563 @default.
• W2056564143 cites W1979988883 @default.
• W2056564143 cites W1980574728 @default.
• W2056564143 cites W1980953487 @default.
• W2056564143 cites W1982154960 @default.
• W2056564143 cites W1999089845 @default.
• W2056564143 cites W2006456243 @default.
• W2056564143 cites W2008599579 @default.
• W2056564143 cites W2015694069 @default.
• W2056564143 cites W2028234509 @default.
• W2056564143 cites W2029635878 @default.
• W2056564143 cites W2034470191 @default.
• W2056564143 cites W2036988959 @default.
• W2056564143 cites W2062835218 @default.
• W2056564143 cites W2066137841 @default.
• W2056564143 cites W2066464941 @default.
• W2056564143 cites W2073452181 @default.
• W2056564143 cites W2078818685 @default.
• W2056564143 cites W2101257013 @default.
• W2056564143 cites W2102633276 @default.
• W2056564143 cites W2114114824 @default.
• W2056564143 cites W2117673880 @default.
• W2056564143 cites W2124022855 @default.
• W2056564143 cites W2126750826 @default.
• W2056564143 cites W2137629557 @default.
• W2056564143 cites W2144953052 @default.
• W2056564143 cites W2146152798 @default.
• W2056564143 cites W2161954129 @default.
• W2056564143 cites W2162135271 @default.
• W2056564143 cites W2165423570 @default.
• W2056564143 cites W2165757245 @default.
• W2056564143 cites W2315240399 @default.
• W2056564143 cites W4211047904 @default.
• W2056564143 cites W4234453747 @default.
• W2056564143 cites W75787445 @default.
• W2056564143 doi "https://doi.org/10.1186/s12885-015-1286-x" @default.
• W2056564143 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4399104" @default.
• W2056564143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25879875" @default.
• W2056564143 hasPublicationYear "2015" @default.
• W2056564143 type Work @default.
• W2056564143 sameAs 2056564143 @default.
• W2056564143 citedByCount "23" @default.
• W2056564143 countsByYear W20565641432016 @default.
• W2056564143 countsByYear W20565641432017 @default.
• W2056564143 countsByYear W20565641432018 @default.
• W2056564143 countsByYear W20565641432019 @default.
• W2056564143 countsByYear W20565641432020 @default.
• W2056564143 countsByYear W20565641432021 @default.
• W2056564143 countsByYear W20565641432022 @default.
• W2056564143 countsByYear W20565641432023 @default.
• W2056564143 crossrefType "journal-article" @default.
• W2056564143 hasAuthorship W2056564143A5007445460 @default.
• W2056564143 hasAuthorship W2056564143A5020255729 @default.
• W2056564143 hasAuthorship W2056564143A5022080735 @default.
• W2056564143 hasAuthorship W2056564143A5065739944 @default.
• W2056564143 hasAuthorship W2056564143A5085834699 @default.
• W2056564143 hasAuthorship W2056564143A5085871218 @default.
• W2056564143 hasAuthorship W2056564143A5086107574 @default.
• W2056564143 hasBestOaLocation W20565641431 @default.
• W2056564143 hasConcept C121608353 @default.
• W2056564143 hasConcept C126322002 @default.
• W2056564143 hasConcept C143998085 @default.
• W2056564143 hasConcept C173396325 @default.
• W2056564143 hasConcept C185592680 @default.
• W2056564143 hasConcept C2776694085 @default.
• W2056564143 hasConcept C2778239845 @default.
• W2056564143 hasConcept C502942594 @default.
• W2056564143 hasConcept C54355233 @default.
• W2056564143 hasConcept C71924100 @default.
• W2056564143 hasConcept C81885089 @default.
• W2056564143 hasConcept C86803240 @default.
• W2056564143 hasConceptScore W2056564143C121608353 @default.
• W2056564143 hasConceptScore W2056564143C126322002 @default.
• W2056564143 hasConceptScore W2056564143C143998085 @default.
• W2056564143 hasConceptScore W2056564143C173396325 @default.
• W2056564143 hasConceptScore W2056564143C185592680 @default.
• W2056564143 hasConceptScore W2056564143C2776694085 @default.
• W2056564143 hasConceptScore W2056564143C2778239845 @default.
• W2056564143 hasConceptScore W2056564143C502942594 @default.
• W2056564143 hasConceptScore W2056564143C54355233 @default.
• W2056564143 hasConceptScore W2056564143C71924100 @default.
• W2056564143 hasConceptScore W2056564143C81885089 @default.
• W2056564143 hasConceptScore W2056564143C86803240 @default.
• W2056564143 hasIssue "1" @default.

• next